We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is an tissue implant that utilizes various aspects of regenerative medicine platform to tre... Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is an tissue implant that utilizes various aspects of regenerative medicine platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Histogenics operates in two geographic regions: The United States (Massachusetts) and Israel (Tel Aviv). Regenerative medicine technologies encompass a variety of therapeutic approaches, including tissue engineering, cell-based therapies, gene therapy, small molecules and biologics, stem cells and biobanking. Show more
BOSTON and JERUSALEM, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) today announced that it has established a U.S. Headquarters in the Boston area and has hired Jonathan...
BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that all proposals related to its proposed merger with Ocugen...
BOSTON, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it convened and then adjourned, without conducting any...
BOSTON, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) (the “Company” or “Histogenics”) today announced that it intends to convene and then adjourn, without conducting...
BOSTON, Mass. and MALVERN, Penn., April 08, 2019 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX) and Ocugen, Inc., a privately held clinical-stage biopharmaceutical company focused...
SOMERVILLE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and...
WALTHAM, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), today provided an update on the NeoCart regulatory pathway based on discussions with the...
WALTHAM, Mass., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- ‒ Histogenics and FDA Continue Discussions on NeoCart® Phase 3 Data and Potential BLA Submission ‒‒ October 2018 Financing Expected to...
WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions